Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to 25.64%.

  • Dexcom's EBITDA Margin rose 86800.0% to 25.64% in Q4 2025 from the same period last year, while for Dec 2025 it was 19.56%, marking a year-over-year increase of 46800.0%. This contributed to the annual value of 19.56% for FY2025, which is 46800.0% up from last year.
  • Dexcom's EBITDA Margin amounted to 25.64% in Q4 2025, which was up 86800.0% from 20.05% recorded in Q3 2025.
  • In the past 5 years, Dexcom's EBITDA Margin ranged from a high of 25.64% in Q4 2025 and a low of 0.09% during Q4 2021
  • Moreover, its 5-year median value for EBITDA Margin was 15.56% (2022), whereas its average is 14.78%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -181900bps in 2021, then skyrocketed by 153000bps in 2022.
  • Over the past 5 years, Dexcom's EBITDA Margin (Quarter) stood at 0.09% in 2021, then surged by 17800bps to 15.38% in 2022, then surged by 36bps to 20.97% in 2023, then dropped by -19bps to 16.96% in 2024, then surged by 51bps to 25.64% in 2025.
  • Its last three reported values are 25.64% in Q4 2025, 20.05% for Q3 2025, and 18.37% during Q2 2025.